Profound Medical Sees Q1 Revenue of $4.85M, Full-Year Revenue Cut 11%
Profound Medical forecasts Q1 revenue of $4.85M and a -$0.27 per share loss when it reports May 7, following a Q4 revenue miss of $5.98M. Analysts have trimmed 2026 revenue estimates by 11% to $30.90M while lifting full-year EPS projections to -$0.96 and set an average $12 price target (70% upside).
1. Q1 Earnings Preview
Profound Medical will release Q1 2026 results on May 7, projecting $4.85 million in revenue and a $0.27 per share loss. This follows a Q4 report of $5.98 million in revenue, which missed analyst estimates by nearly 20%.
2. 2026 Forecast Revisions
Analysts have reduced full-year 2026 revenue forecasts by 11% to $30.90 million over the past 90 days, while improving EPS estimates from -$1.24 to -$0.96 per share. Meanwhile, 2027 revenue and earnings projections have been nudged higher to $49.84 million and -$0.87 per share, respectively.
3. Valuation Outlook
Brokerages assign an average price target of $12, implying about 70% upside, and maintain an average recommendation of 1.6 (Outperform). An alternative fair value model estimates a one-year value near $30.80, suggesting over 330% upside.